Lyra Therapeutics, Inc. Stock Price, News & Analysis

Lyra Therapeutics announced positive topline results from its pharmacokinetic study of LYR-210, a novel treatment for chronic rhinosinusitis (CRS). The study, involving 24 patients over 56 days, confirmed LYR-210's safety and established a pharmacokinetic profile supporting a 505(b)(2) New Drug Application pathway. Both dosage groups (2500 µg and 7500 µg) showed well-tolerated results, with plasma concentrations significantly below established safety thresholds. The company anticipates initiating a Phase 3 clinical program by year-end, underscoring LYR-210's potential as a non-invasive treatment option for CRS patients.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced a successful End-of-Phase 2 meeting with the FDA regarding LYR-210 for chronic rhinosinusitis (CRS). The upcoming Phase 3 program will include 350 subjects across two trials, aiming to demonstrate improvement in CRS symptoms at week 24. Encouragingly, previous trials indicated significant symptom reduction. The FDA's approval of the 505(b)(2) application pathway allows for an efficient study design, potentially incorporating Asian patients, and suggests a clear path forward for LYR-210’s clinical development.

Lyra Therapeutics (LYRA) has entered a strategic partnership with LianBio to develop and commercialize LYR-210, an anti-inflammatory drug for chronic rhinosinusitis (CRS), across Greater China, South Korea, Singapore, and Thailand. Lyra will receive an upfront payment of $12 million and could earn up to $135 million based on future milestones. The agreement allows LianBio to license LYR-210 and potentially LYR-220 in the region. This collaboration aims to address the significant unmet medical need for CRS patients, with an estimated 88 million adult CRS patients in China.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced that its President and CEO, Maria Palasis, Ph.D., will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 11:30 am EDT. Investors can access a live audio webcast from the company's website, with a replay available for 30 days. Lyra focuses on drug delivery solutions for ENT diseases, with its lead candidate, LYR-210, targeting chronic rhinosinusitis. The company also develops LYR-220 for post-surgery CRS patients, leveraging its XTreo™ platform.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) announces that CEO Maria Palasis, Ph.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:00 AM EDT. This event will be accessible via a live audio webcast on the company's website, with replays available for 30 days. Lyra focuses on integrated drug and delivery solutions for ENT diseases, notably developing LYR-210 for chronic rhinosinusitis and LYR-220 for patients post-surgery. Their XTreo™ platform aims to improve localized drug delivery.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported Q1 2021 financial results, highlighting the positive full data set from its LANTERN Phase 2 Study of LYR-210 for chronic rhinosinusitis, presented at COSM 2021. The study showed effectiveness in non-polyp and polyp patients, with 100% achieving SNOT-22 MCID at week 24. The company has $66.1 million in cash, down from $74.6 million, with R&D expenses rising to $4.8 million. A Phase 3 trial for LYR-210 is planned by year-end, pending FDA approval. Lyra expects sufficient cash to fund operations into 2023.

Lyra Therapeutics (Nasdaq: LYRA) announced that CEO Maria Palasis, Ph.D., will present at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 4:15 p.m. ET. The presentation can be accessed via the company's website, with a replay available for 30 days afterward. Lyra is focused on developing innovative drug delivery solutions for ENT diseases, notably its lead candidate LYR-210 for chronic rhinosinusitis. The company believes its XTreo™ platform may extend its applications beyond ENT treatments.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) will announce its Q1 2021 financial results on May 11, 2021, after market close and host a conference call at 4:30 p.m. ET. Lyra focuses on developing integrated drug delivery solutions for ENT diseases, notably its lead product candidate LYR-210, designed for chronic rhinosinusitis treatment. The press release emphasizes the company's ongoing clinical trials and innovation in drug delivery using its XTreo™ platform, which aims to provide sustained medication release.

Lyra Therapeutics (Nasdaq: LYRA) presented data from its Phase 2 LANTERN study of LYR-210, targeting chronic rhinosinusitis (CRS), at the Combined Otolaryngology Spring Meetings 2021. LYR-210 is a long-acting, non-invasive alternative for patients who failed medical management. The study showed significant improvement in both polyp and non-polyp patients, with 100% achieving minimal clinically important difference in symptoms. Key findings included a reduction in rescue medication use and improved imaging results. The data supports further development towards a pivotal Phase 3 trial.